Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (2946)	11/23/1997 6:04:00 PM
From: Oliver & Co	Read Replies (1) of 6136

John W. here is to "Hit Hard, Hit Early" "Special Type of Immune Cell May Be Key to Avoiding AIDS" New York Times (11/21/97) P. A18 New findings from researchers at Boston's Massachusetts General Hospital suggest that high levels of HIV-specific helper T cells may be critical for the body's control of the virus. The researchers, led by Dr. Bruce Walker, reported in Friday's issue of the journal Science that tests using antiviral drugs to treat people recently infected with HIV show that the drugs cause the viral load to drop, allowing the body's immune systems to produce T cells that attacked HIV. "This suggests there is a window of time during the acute phase of infection when antiviral treatment can rescue the helper T cell response to HIV," explained Walker.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next